HB 471 would create a new chapter in Florida Statutes, titled the “Florida End-of-Life Options Act” and placed within a new chapter on “Personal Autonomy.” The bill establishes a legal process for certain terminally ill adults to request and self-administer medication intended to end their lives in a peaceful manner. It defines key terms such as terminal condition, mental capacity, informed decision, consulting physician, and qualified patient, and sets out eligibility criteria including Florida residency, age 18 or older, a medically confirmed terminal condition expected to cause death within six months, mental capacity, voluntariness, and the ability to self-administer the medication.
The bill requires a structured request process: two oral requests separated by at least 15 days, followed by a written request, with a 48-hour waiting period before a prescription may be written unless death is expected within that period. It also allows oral requests by telehealth when clinically appropriate. The written request must be witnessed by two individuals, with restrictions on who may serve as a witness, and the patient may rescind the request at any time and in any manner. Physicians must confirm diagnosis, prognosis, capacity, voluntariness, informed decision-making, and residency, and must refer patients for mental health counseling when indicated. The bill also requires reporting to the Department of Health, annual public reporting of aggregated data, and rules for disposal of unused medication and for listing the underlying terminal condition, rather than the medication, on the death certificate.
HB 471 would significantly affect Florida law by creating new statutory protections and exceptions around end-of-life medication, while also amending the criminal code to exempt conduct authorized under the act from the state’s assisted self-murder statute. It would also void certain contract, will, and insurance provisions that interfere with a person’s ability to request or rescind a request for medication, and prohibit insurers from denying or discriminating in coverage based on participation in the act. The bill further provides immunity for good-faith compliance, creates penalties for coercion or forgery, and sets rules for health care facilities and employers to permit or restrict participation on their premises under specified notice and due process requirements.
The overall sentiment reflected in the bill text is strongly supportive of patient autonomy and relief from suffering, with the Legislature’s findings emphasizing self-determination, terminal illness, and intolerable pain. At the same time, the bill is highly regulated and cautious in structure, suggesting an effort to address concerns about coercion, capacity, fraud, and institutional participation. The fact that the bill died in the Health Professions & Programs Subcommittee indicates it did not advance, which is consistent with the sensitivity and controversy typically associated with medical aid-in-dying legislation.
The main points of contention are likely to center on whether Florida should authorize physician-assisted dying at all, and if so, under what safeguards. The bill anticipates objections involving coercion, undue influence, mental health screening, conflicts of interest, insurance discrimination, and the role of health care facilities and providers who object to participation. It also creates a limited claim for governmental costs if a person dies in a public place, which could raise additional concerns about implementation and liability. Overall, the measure attempts to balance autonomy with procedural safeguards, but the subject matter remains ethically and politically divisive.
HB 471 would create an entirely new statutory framework in chapter 764, Florida Statutes, governing end-of-life medication requests for qualifying terminally ill adults. It would also amend section 782.08 to exempt conduct authorized under the new chapter from Florida’s criminal prohibition on assisting self-murder, while adding related rules on reporting, death certificates, disposal of unused medication, insurance protections, and enforceable limits on coercion and fraud. The bill would affect physicians, pharmacists, mental health professionals, health care facilities, insurers, patients, and estates, and would require the Department of Health to administer reporting and publish annual aggregate data.
The bill’s text reflects a generally supportive sentiment toward end-of-life choice and personal autonomy, framing the proposal as a humane option for adults with terminal conditions who want to avoid prolonged suffering. At the same time, the detailed procedural safeguards, witness requirements, mental health referrals, and anti-coercion provisions show that the proposal was drafted with substantial caution. No committee transcript or vote record is available, but the bill’s death in the Health Professions & Programs Subcommittee suggests it did not gain enough support to advance.
The most likely areas of contention are the moral and legal permissibility of physician-assisted dying, the adequacy of safeguards against coercion or impaired judgment, and the role of health care institutions and providers who object to participation. Opponents may focus on risks to vulnerable patients, the possibility of abuse, and conflicts with professional ethics or religious beliefs, while supporters are likely to emphasize autonomy, dignity, and relief from suffering. Additional friction points include insurance and contract provisions, facility-level restrictions on participation, and whether the bill’s reporting and oversight mechanisms are sufficient to prevent misuse.